LCG
SAGE

Lisanti Capital Growth’s Sage Therapeutics SAGE Stock Holding History

Lisanti Capital Growth’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6,390
Closed -$1.03M – 151
2018
Q1 		$1.03M Buy
+6,390
New +$1.08M 0.5% 84
2017
Q3 		– Sell
-11,123
Closed -$886K – 130
2017
Q2 		$886K Buy
11,123
+2,388
+27% +$173K 0.59% 78
2017
Q1 		$621K Sell
8,735
-1,885
-18% -$110K 0.89% 61
2016
Q4 		$542K Buy
+10,620
New +$501K 0.65% 74

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Lisanti Capital Growth's SAGE Position: Q2 2018 in Review

Lisanti Capital Growth sold out of Sage Therapeutics (SAGE) in Q2 2018, closing a stake of 6,390 shares — an estimated $1.03M sold.

Lisanti Capital Growth first reported a position in SAGE in Q4 2016 and held it in 4 quarters. The position peaked at $1.03M in Q1 2018. 269 funds tracked by Wall St. Rank hold SAGE as of Q2 2018.

  • Lisanti Capital Growth reported no remaining Sage Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Lisanti Capital Growth sold 6,390 Sage Therapeutics shares in Q2 2018, an estimated $1.03M.
  • Lisanti Capital Growth first reported a position in Sage Therapeutics in Q4 2016 and held it in 4 quarters.
  • Lisanti Capital Growth's Sage Therapeutics position peaked at $1.03M in Q1 2018.
  • 269 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2018.

Based on Lisanti Capital Growth's 13F filing for Q2 2018, filed 13 Aug 2018.